When
Gary Farmer was 45, his doctors told him he had a terminal illness
and would live only another two to five years....That was 1996.
Farmer has, so far, beaten those odds and along the way has discovered
artistic talents that he never knew existed.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information
resource for people dealing with PH -- THIRD edition to be available
in August!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Bruce Brundage, a physician with a deep knowledge of
PH, edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
ALLSCHWIL/BASEL,
Switzerland, July 27, 2004 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today
announced its financial results for the first six months of 2004. With
total net revenues for H1 2004 of CHF 215.0 million (H1 2003: CHF 131.6
m) and operating expenses of CHF 179.9 million (H1 2003: 117.4 m),
the company reported an operating profit of CHF 35.1 million (H1 2003:
CHF 14.2 m). The net profit for H1 2004 was CHF 39.0 million (H1 2003:
CHF 11.0 m).
Andrew J. Oakley, Chief Financial Officer commented: "The results
of the first half of 2004 are very encouraging, as the company advances
in all areas. Tracleer(r) sales continue to grow. We continue to invest
substantially in the future of Actelion with multiple late-stage clinical
trials and in new innovative compounds. Actelion does all that whilst
delivering on the bottom line."
Our lives are in our stories. Visit the Our Journeys section of
the PHA website...and, if you're so inclined, enrich the experience
for yourself and others by posting your story. http://www.phassociation.org/Our_Journeys/
Myogen
to Announce 2004 Second Quarter Results on August 5, 2004
DENVER, July 27 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG
- News), a biopharmaceutical company focused on the discovery, development
and commercialization of small molecule therapeutics for the treatment
of cardiovascular disease, today announced that it will report 2004 second
quarter results on Thursday, August 5, 2004, before the U.S. financial
markets open.
Myogen is a biopharmaceutical company focused on the discovery, development
and commercialization of small molecule therapeutics for the treatment
of cardiovascular disorders. Myogen currently markets one product in
Europe for the treatment of acute decompensated heart failure and has
three product candidates in late-stage clinical development: enoximone
capsules for the treatment of chronic heart failure, ambrisentan for
the treatment of pulmonary arterial hypertension and darusentan for the
treatment of resistant hypertension.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
